Sharon Benzeno Sells Shares of Adaptive Biotechnologies Corporation $ADPT
Key Points
- Sharon Benzeno sold 103,295 shares of Adaptive Biotechnologies Corporation ($ADPT).
- $ADPT last traded around $22.16.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Sharon Benzeno, Chief Commercial Ofc Imm Med at Adaptive Biotechnologies Corporation ($ADPT), sold 103,295 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Adaptive Biotechnologies Corporation Stock Down 12.0%
Shares of Adaptive Biotechnologies Corporation ($ADPT) traded around $22.16 on Wednesday, down 12.0% for the day.
Adaptive Biotechnologies Corporation Earnings
Analysts Set New Price Targets
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Get Adaptive Biotechnologies Corporation alerts
New 13F filings, insider trades, and analyst moves on $ADPT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.